Prevention of cancer through immunization: Prospects and challenges for the 21st century

Frazer, Ian H.; Lowy, Doug; Schiller, John T.

doi:10.1002/eji.200737820

Cited by 41 publications

(33 citation statements)

References 53 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Two injectable VLP-based HPV vaccines (Gardasil and Cervarix) have recently been shown to confer protection against HPVassociated cervical intraepithelial neoplasia and adenocarcinoma (1,2). IgG Abs transuding from blood into genital tissues and secretions are considered the main effector mechanism conferring protection.…”

Section: Discussionmentioning

confidence: 99%

“…To date, only two injectable vaccines against a sexually transmissible disease, genital human papillomavirus infection, have been registered recently and appear to confer protection by genital IgG Abs derived from the circulation (1,2). An ideal vaccine against genital infections should also induce mucosal immune responses and local immunological memory, attributes that are generally better achieved by mucosal immunization (3)(4)(5)(6).…”

mentioning

confidence: 99%

See 1 more Smart Citation

Sublingual Immunization with Nonreplicating Antigens Induces Antibody-Forming Cells and Cytotoxic T Cells in the Female Genital Tract Mucosa and Protects against Genital Papillomavirus Infection

Çuburu

Kweon

Hervouet

et al. 2009

The Journal of Immunology

100

View full text Add to dashboard Cite

We have recently reported that the sublingual (s.l.) mucosa is an efficient site for inducing systemic and mucosal immune responses. In this study, the potential of s.l. immunization to induce remote Ab responses and CD8+ cytotoxic responses in the female genital tract was examined in mice by using a nonreplicating Ag, OVA, and cholera toxin (CT) as an adjuvant. Sublingual administration of OVA and CT induced Ag-specific IgA and IgG Abs in blood and in cervicovaginal secretions. These responses were associated with large numbers of IgA Ab-secreting cells (ASCs) in the genital mucosa. Genital ASC responses were similar in magnitude and isotype distribution after s.l., intranasal, or vaginal immunization and were superior to those seen after intragastric immunization. Genital, but not blood or spleen, IgA ASC responses were inhibited by treatment with anti-CCL28 Abs, suggesting that the chemokine CCL28 plays a major role in the migration of IgA ASC progenitors to the reproductive tract mucosa. Furthermore, s.l. immunization with OVA induced OVA-specific effector CD8+ cytolytic T cells in the genital mucosa, and these responses required coadministration of the CT adjuvant. Furthermore, s.l. administration of human papillomavirus virus-like particles with or without the CT adjuvant conferred protection against genital challenge with human papillomavirus pseudovirions. Taken together, these findings underscore the potential of s.l. immunization as an efficient vaccination strategy for inducing genital immune responses and should impact on the development of vaccines against sexually transmitted diseases.

show abstract

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 99%

Sublingual Immunization with Nonreplicating Antigens Induces Antibody-Forming Cells and Cytotoxic T Cells in the Female Genital Tract Mucosa and Protects against Genital Papillomavirus Infection

Çuburu

Kweon

Hervouet

et al. 2009

The Journal of Immunology

100

View full text Add to dashboard Cite

show abstract

“…59,60 The vaccine still faces numerous obstacles, including cost, cultural, and religious beliefs of the at-risk population. 61 …”

Section: Human Papilloma Virusmentioning

confidence: 97%

“…Preliminary reports indicate a small decrease in the incidence of HCC; however, because the peak age for HCC is 40 to 60 years of age, theoretically a larger drop would be expected 30 to 40 years after the implementation of universal vaccination against hepatitis B, which began in the late 1990's. 61 …”

Section: Hepatitis Bmentioning

confidence: 97%

Preventing Cancer

Molokhia

Perkins

2008

Primary Care: Clinics in Office Practice

View full text Add to dashboard Cite

Advancements in management protocols and chemotherapeutics have improved outcomes for patients diagnosed with cancer. Cancer, however, continues to claim many lives annually in the United States and around the world. There is a large body of evidence that is strong and consistent that through modification of diet and lifestyle habits, cancer can be a preventable disease. This article discusses these changes and highlights the evidence for and against implementing them.

show abstract

“…Annually, this disease causes approximately 234,000 deaths, 40,000 of which occur in developing countries 1. Inconsistencies in the incidence/mortality ratio between countries with different economic resources are a consequence of marginal investment in screening programs and limited access to vaccines against human papilloma virus (HPV), which is associated with 90% of invasive neoplasms 2. Although information regarding the epidemiology of the disease in Latin America is limited, CC is known to be the second most common cause of cancer‐related death among women from Colombia and Mexico 3, 4, where locally advanced tumors (clinical stages IB2 to IVA according to the International Federation of Gynecology and Obstetrics [FIGO] staging classification) account for 60% of cases; lesions in early stages generally predominate in countries with greater wealth 3, 4, 5.…”

Section: Introductionmentioning

confidence: 99%

Epithelial–mesenchymal transition, proliferation, and angiogenesis in locally advanced cervical cancer treated with chemoradiotherapy

Rojas‐Puentes

Cardona²,

Carranza³

et al. 2016

Cancer Medicine

View full text Add to dashboard Cite

We evaluated the association between epithelial–mesenchymal transition (EMT)‐derived markers and expression of proteins associated with cell proliferation and tumor growth, as well as their prognostic roles, in 61 patients (mean age 52 ± 10 years) with locally advanced cervical cancer, all of whom were treated with chemoradiation and intracavitary brachytherapy. We used immunohistochemical analysis to assess the expression of proteins targeted in our investigation. Various statistical analyses were then conducted to assess protein marker associations with survival outcomes. Forty‐six percent of the patients were positive for human papilloma virus. Median progression‐free survival (PFS) was 6.6 months (95% confidence interval [CI]: 4.0–9.1, whereas overall survival (OS) was 30.0 months (95% CI: 11–48). Multivariate analysis demonstrated that vascular endothelial growth factor (VEGF) (P = 0.002), epidermal growth factor receptor (EGFR) (P = 0.001), and TWIST2 (P = 0.001) expression levels, as well as a tumor size <6 cm (P = 0.02), influenced OS. Changes in TWIST2 levels and loss of E‐cadherin expression were correlated with VEGF and EGFR levels; furthermore, patients with high TWIST2 expression had shorter OS (P = 0.0001), as those with loss of E‐cadherin (P = 0.02). OS was even shorter when positive EGFR or VEGF expression was related with EMT markers (positive EGFR + negative E‐cadherin: median 14 months, 95% CI: 3–24; negative EGFR + positive E‐cadherin: median 31 months, 95% CI: 14–NA; P = 0.02.). The presence of EMT markers was associated with proliferative and pro‐angiogenic protein expression and influenced the prognosis of locally advanced cervical cancer.

show abstract

Prevention of cancer through immunization: Prospects and challenges for the 21st century

Cited by 41 publications

References 53 publications

Sublingual Immunization with Nonreplicating Antigens Induces Antibody-Forming Cells and Cytotoxic T Cells in the Female Genital Tract Mucosa and Protects against Genital Papillomavirus Infection

Sublingual Immunization with Nonreplicating Antigens Induces Antibody-Forming Cells and Cytotoxic T Cells in the Female Genital Tract Mucosa and Protects against Genital Papillomavirus Infection

Preventing Cancer

Epithelial–mesenchymal transition, proliferation, and angiogenesis in locally advanced cervical cancer treated with chemoradiotherapy

Contact Info

Product

Resources

About